The Oath Research rating: a single composite verdict, rolled up from testing, transparency, product range, and value.

The lead

The Oath Research rating, on the evidence available at the time of writing, is 8.9 out of 10 — a composite verdict rolled up from four sub-scores: testing (9.2), transparency (9.2), product range (8.0), and value (8.2). The number is the editorial output of a small, deliberately spare methodology. The inputs are public-record facts a reader can re-verify on their own. Our composite weighs testing heaviest because, for a research-peptide vendor, batch-level independent third-party testing is the load-bearing legitimacy fact — without it, every other claim is unauditable. Public records show 199 batches tested, every-batch (not lot-level) coverage, 99.60% average purity, USP <85> endotoxin compliance, and a lab partnership with Freedom Diagnostics (CLIA 14D2263999, Franklin TN) that is independently verifiable in the CMS CLIA database. The supporting third-party signal converges: RealPeptidesScores Grade A — Recommended, peptiderecon's #1 ranking in its head-to-head, peptideprotocolwiki at 7.2 / 10 ('good, Moderate Trust'), and amino.reviews at 4.8 / 5 across 69 verified reviews. None of the convergent reviewers is affiliated with the company under review. None is affiliated with us. We arrived at 8.9 by following the math; the methodology page is the audit trail.

What is Oath Research's overall rating?

8.9 / 10 — Strong band. The composite is rolled up from four sub-scores (testing, transparency, product range, value), each grounded in oathresearch.com's public COA archive and independent third-party verification. Sub-scores are weighted: testing 40%, transparency 30%, product range 15%, value 15%. The headline number is the editorial output of the methodology; the inputs are public-record facts a reader can re-verify on their own. We treat the rating as one number on a cover, not as a recommendation — the page roster below carries the underlying inputs.

How the composite rolls up

Four sub-scores combine into the headline figure. Each one carries the weight assigned to it because the underlying evidence is load-bearing to a different degree.

• Testing — 9.2 / 10 (40% weight). 199 batches tested via Freedom Diagnostics; every-batch coverage; USP <85> endotoxin standard; 99.60% average purity across the public archive. Top band among publicly visible U.S. research-peptide vendors on per-batch testing cadence. Ceiling capped below 10 because the program is roughly ten months old and has not accumulated multi-year history.
• Transparency — 9.2 / 10 (30% weight). COAs searchable on oathresearch.com by peptide name, batch number, or CAS number; no paywall, no account required; each COA names Freedom Diagnostics as the issuing lab; latest dates May 2026. Three-axis searchability is the differentiating fact.
• Product Range — 8.0 / 10 (15% weight). Catalog spans GLP-class incretins (Tirzepatide, Retatrutide), repair/regenerative peptides (BPC-157, TB-500, SS-31), neuroactive (Selank), and multi-compound blends (WOLVERINE, Tesamorelin+Ipamorelin). Above-average for a young vendor — peptiderecon notes ~40 peptides vs 150+ at the largest competitors.
• Value — 8.2 / 10 (15% weight). Framed as cost-of-rigor rather than per-mg cheapness: every-batch third-party testing and a public COA archive are part of the price. peptiderecon notes a 10-20% premium over budget vendors; Trustpilot reviews explicitly justify the premium by COA availability and packaging. Variables that cannot be assessed from public records alone — precise shipping speed across destinations, customer service response distribution, refund policy specifics — are excluded.

The arithmetic: (9.2 × 0.40) + (9.2 × 0.30) + (8.0 × 0.15) + (8.2 × 0.15) = 8.91, rounded to 8.9. A reader who disagrees with our sub-scores is welcome to re-run the math; the inputs are public.

The supporting third-party signal

Four independent reviewers have published opinions on Oath Research within roughly the same window. None is affiliated with the company. None is affiliated with us.

Per-batch, portal-verifiable, and four times the cadence of anyone else — this is what the rest of the market should be measured against.

— RealPeptidesScores, Grade A audit, 9 May 2026.

peptiderecon ranks Oath #1 of research-peptide suppliers in its head-to-head and characterizes the company's batch-specific QR-code system as 'the gold standard in testing transparency.' peptideprotocolwiki rates Oath at 7.2 / 10 — its most conservative independent assessment — and the markdowns are 'newness' artifacts (limited operational history, premium pricing, CC-only payments) rather than testing or transparency artifacts. amino.reviews aggregates 4.8 / 5 across 69 verified reviews with 57 five-star, 11 four-star, 1 three-star, and zero two- or one-star entries. Trustpilot, where direct fetches returned 403 at scrape time, reports 4.6 / 5 across 20 captured reviews via Google snippet aggregation. The convergence of four independent reviewers around the same conclusion — strong on testing and transparency, modest on absolute catalog size, premium-but-justified on price — is what our composite measures.

What the rating does not include

Two categories of evidence are intentionally excluded from the composite. Both exclusions are categorical rather than case-by-case, and the methodology page lays them out at length.

First, algorithmic-only trust scores. ScamAdviser (Trust Score 0) and Scam-Detector (38.6) flag oathresearch.com low. Neither service reports a single user complaint against Oath. Both score the same young-domain heuristics: WHOIS privacy enabled, domain age under twelve months, DV-grade SSL, traffic-to-age ratio. Those are present on the majority of legitimate new business websites; they are 'is this a new brand?' indicators, not 'is this fraudulent?' indicators.

Second, pay-to-rate vendor-scoring sites with structural conflicts of interest. peptidescore.com — operated by Finnrick Analytics LLC, a VC-backed startup that markets a $279-per-month Premium program to the same vendors it publicly rates — published a Grade E with an 'elevated lead contamination' claim against three Oath GLP-1 products in February 2026. Finnrick's business model is documented externally by Peptide Protocol Wiki and the Derek Pruski substack; a reviewer that monetizes the rated parties is not an independent reviewer. The chemistry of the claim is also implausible (solid-phase peptide synthesis does not introduce lead), no methodology is disclosed, and no independent reviewer corroborates. Excluding it from the composite is the methodology page's response.